Objective-Arteriovenous fistulae (AVF) remain the optimal conduit for hemodialysis access but continue to demonstrate poor patency and poor rates of maturation. We hypothesized that CD44, a widely expressed cellular adhesion molecule that serves as a major receptor for extracellular matrix components, promotes wall thickening and extracellular matrix deposition during AVF maturation. Approach and Results-AVF were created via needle puncture in wild-type C57BL/6J and CD44 knockout mice. CD44 mRNA and protein expression was increased in wild-type AVF. CD44 knockout mice showed no increase in AVF wall thickness (8.9 versus 26.8 μm; P=0.0114), collagen density, and hyaluronic acid density, but similar elastin density when compared with control AVF. CD44 knockout mice also showed no increase in vascular cell adhesion molecule-1 expression, intercellular adhesion molecule-1 expression, and monocyte chemoattractant protein-1 expression in the AVF compared with controls; there were also no increased M2 macrophage markers (transglutaminase-2: 81.5-fold, P=0.0015; interleukin-10: 7.6-fold, P=0.0450) in CD44 knockout mice. Delivery of monocyte chemoattractant protein-1 to CD44 knockout mice rescued the phenotype with thicker AVF walls (27.2 versus 14.7 μm; P=0.0306), increased collagen density (2.4-fold; P=0.0432), and increased number of M2 macrophages (2.1-fold; P=0.0335). Conclusions-CD44 promotes accumulation of M2 macrophages, extracellular matrix deposition, and wall thickening during AVF maturation. These data show the association of M2 macrophages with wall thickening during AVF maturation and suggest that enhancing CD44 activity may be a strategy to increase AVF maturation. Visual Overview-An online visual overview is available for this article. regulatory roles in numerous circumstances, including effects on cellular proliferation and differentiation, as well as creation and maintenance of 3-dimensional tissue structures. 6 ECM remodeling plays a distinct role in intimal thickening and vascular remodeling that occurs during AVF maturation. 3, 5, 7 CD44 is a widely expressed cellular adhesion molecule that serves as a major receptor for ECM components such as hyaluronic acid (HA); HA has been linked to vascular remodeling after injury, as it accumulates during neointimal hyperplasia.
T he US Renal Data System reported that the number of patients with end-stage renal disease in the United States continues to increase and exceeds 600 000 in 2013. 1 Patients with end-stage renal disease are typically dependent on hemodialysis as renal replacement therapy because the scarcity of organs available limits renal transplantation to less than 20 000 per year. 1 A durable vascular access is vitally important for patients undergoing hemodialysis. The autologous arteriovenous fistula (AVF) is currently the preferred choice for vascular access because of lower rates of infection, thrombosis, and access-related expenditures compared with synthetic arteriovenous grafts. However, patency rates at 1 year are typically <60% and it is not uncommon for patients to undergo repeated vascular interventions and surgical procedures. 2 In fact, these numbers may be overly optimistic because they do not include fistulae that fail to mature, that is, dilate and thicken adequately to support the increased flows necessary to support successful hemodialysis; a significant number of fistulae (28%-53%) fail to mature adequately. 3 The large number of AVF that fail to mature reflects our poor understanding of the biology of maturation, that is, understanding the mechanisms by which the vein adapts to the unique arterial-like environment of the fistula.
We previously described a mouse AVF model that recapitulates human AVF maturation with a distinct maturation phase. 4 We used this model to show temporal expression patterns of the extracellular matrix (ECM) proteins during AVF maturation. 5 Beyond structural support, the ECM plays regulatory roles in numerous circumstances, including effects on cellular proliferation and differentiation, as well as creation and maintenance of 3-dimensional tissue structures. 6 ECM remodeling plays a distinct role in intimal thickening and vascular remodeling that occurs during AVF maturation. 3, 5, 7 CD44 is a widely expressed cellular adhesion molecule that serves as a major receptor for ECM components such as hyaluronic acid (HA); HA has been linked to vascular remodeling after injury, as it accumulates during neointimal hyperplasia. 8 CD44 promotes adhesion of leukocytes to endothelial cells, 9 induces macrophage chemokine secretion, and regulates vascular smooth muscle cell proliferation and migration. 10 CD44 may promote atherosclerosis by mediating inflammatory cell recruitment and activation of leukocytes and vascular smooth muscle cells. 9, 11, 12 We have previously reported that CD44 regulates vascular integrity and inflammation. 13, 14 Because these functions are likely to be active during venous remodeling such as occurs during AVF maturation in the fistula environment, we hypothesized that CD44 plays a role during venous remodeling, increasing ECM deposition, and promoting inflammatory cell recruitment during AVF maturation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CD44 Expression Increases During AVF Maturation
As AVF maturation in the arterial environment is associated with dilation and thickening of the vein wall, we performed a microarray analysis to determine whether there were global increases in the expression of genes coding for the ECM. 5 An AVF was created between the aorta and the inferior vena cava in mice, and the venous limb of the AVF was removed on postoperative day 7 and patterns of gene expression were compared with the inferior vena cava of sham-operated mice. We previously reported 1196 genes with significantly changed expression in the AVF compared with vein; of these 1196 genes, 14 genes encoding for matrix proteins showed increased expression, including CD44 which showed a 2.1-fold increase. 5 Because CD44 is a receptor for HA, and regulates inflammation, we assessed CD44 expression during AVF maturation. Quantitative real-time polymerase chain reaction showed significantly increased expression of CD44 mRNA in the venous limb of the AVF compared with shamoperated mice, with maximal expression of CD44 on days 1 and 7 ( Figure 1A and Table 1 ). Protein expression of CD44 was similarly elevated in the venous limb of the AVF, with elevation of the CD44s and CD44v fragments ( Figure 1B and  1C) . The time course of CD44 protein expression was assessed using immunohistochemistry; CD44 protein expression did not significantly increase in the AVF wall on day 1 or 7, but was increased at day 21 ( Figure 1D ). Immunofluorescence confirmed significantly increased CD44 immunoreactivity in the venous, but not the arterial limb, of the AVF compared with sham-operated mice at day 21 ( Figure 1E through 1G) . These results show that CD44 expression is elevated in the venous limb of the AVF at the same time as the limb adapts to the arterial environment.
Lack of Wall Thickening During AVF Maturation in CD44 Knockout Mice
To determine whether CD44 plays a mechanistic role in venous remodeling during AVF maturation, AVF were made in both control and CD44 knockout mice. There were no significant differences at baseline in venous diameter, wall thickness, or blood flow, as well as arterial diameter, wall thickness, or blood flow, between control and CD44 knockout mice ( Table 2 ). The patency rate of AVF performed in CD44 knockout mice was 93.4% (15/16) at day 1, which was similar to the 100% (12/12) patency rate in wild-type (WT) mice (P>0.9999, Fisher exact test); the patency rates at day 21 were also similar (50% [8/16] versus 50% [6/12] ; P>0.9999). The diameter of the venous limb of the AVF was not different in control or CD44 knockout mice (Figure 2A ), although the diameter of the arterial limb increased less in CD44 knockout mice compared with control mice ( Figure 2B ). However, by postoperative day 21, the wall thickness of the venous limb of the AVF was not increased in CD44 knockout mice compared with the increase in AVF wall thickness in control mice ( Figure 2C and 2D) ; similarly, there was less reduction in the wall thickness of the arterial limb of the AVF in CD44 knockout mice compared with control mice ( Figure 2C and 2E). Although there were no differences in CD31 immunoreactivity in both the venous and the arterial endothelium of the AVF between control mice and CD44 knockout mice, the venous limb of the AVF in CD44 knockout mice was characterized by no change in α-actin density in CD44 knockout mice compared with the increased α-actin density in control mice ( Figure 2C and 2L), and there was no difference in the α-actin density of the arterial limb in CD44 knockout and control mice ( Figure 2C and 2M) .
Because the wall thickness of the AVF venous limb did not change over time in CD44 knockout mice ( Figure 2C and 2D) , we examined components of the ECM to determine whether deposition of any of these were similarly unchanged. There was no increase in collagen deposition in the venous limb of CD44 knockout mice compared with increased collagen deposition in control mice ( Figure 2C , 2F, and 2G); specific immunostaining for collagen-I and collagen-III in control and CD44 knockout fistulae showed that both collagen-I and collagen-III deposition were less prominent at day 21 in CD44 knockout fistulae compared with control fistulae ( Figure IA in the online-only Data Supplement). However, there was no difference in elastin density in either the venous or arterial limbs between control and CD44 knockout mice ( Figure 2C , 2H, and 2I). The expression of HA, the matrix component that binds CD44 as a major ligand, showed no change over time in the venous limb of the AVF in CD44 knockout mice, whereas it was increased in control Figure 2C and 2J). This difference was not observed in the arterial limb of the AVF ( Figure 2C and 2K) . Similarly, the density of Alcian blue staining showed less increase in the venous limb of the AVF in CD44 knockout mice compared with control mice ( Figure 2N ), confirming less deposition of acidic polysaccharides such as HA. The mRNA expression of hyaluronan synthase 2, the isoform of HA synthase that is the rate limiting step for HA synthesis, was elevated in the venous limb of the AVF when compared with sham mice (1.366-fold increase, P=0.0490; microarray), and showed no change in the venous limb of AVF of CD44 knockout mice, whereas that of control mice increased over time ( Figure 2O ). These results show that the venous limb of AVF in CD44 knockout mice does not increase wall thickness and does not synthesize ECM components as do AVF in control mice, consistent with a mechanistic role for CD44 in AVF maturation.
Loss of Inflammation During AVF Maturation in CD44 Knockout Mice
Because CD44 may play a mechanistic role in wall thickening of the venous limb during AVF maturation, and CD44 can stimulate inflammation, we determined whether any inflammatory markers were not induced in the venous limb during AVF maturation in CD44 knockout mice. 12 The mRNA expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, but not E-selectin, were induced on day 21 in the venous AVF limb of control mice, but not CD44 knockout mice ( Figure 3A There was increased mRNA expression of the macrophage marker CD68, but not the leukocyte markers CD45 or CD3, in the venous AVF limb of control mice, but not CD44 knockout mice ( Figure 3D through 3F) . Similarly, there were fewer adventitial cells that were immunoreactive for CD68 in the venous AVF limb of CD44 knockout mice compared with control mice (Figure 3H and 3I ). There was a similar amount of mRNA expression of the M1 markers tumor necrosis factor-α and inducible nitric oxide synthase in the venous AVF limb of CD44 knockout and control mice ( Figure 4A and 4B) ; however, there was no increase in mRNA expression of the M2 markers transglutaminase-2 and interleukin-10 in the venous AVF limb of CD44 knockout compared with the increased expression in control mice ( Figure 4C and 4D) . Similarly, there were fewer cells that were immunoreactive for transglutaminase-2 and interleukin-10 in the venous AVF limb of CD44 knockout mice compared with control mice (Figure 4E through 4G ). There were also fewer adventitial cells immunoreactive for monocyte chemoattractant protein-1 (MCP-1), and less MCP-1 mRNA expression, in the venous AVF limb of CD44 knockout mice compared with control mice (Figure 3G , 3J, and 3K). These results show that the venous limb of the AVF in CD44 knockout mice does not show increased inflammatory markers, angiogenesis, and M2 macrophages as they are increased in control mice, consistent with CD44 stimulating or permissive for inflammation during AVF maturation.
MCP-1 Increases Venous AVF Wall Thickness and M2 Macrophages
As the loss of CD44 is associated with no increase in AVF venous wall thickness ( Figure 2 ) and no increased MCP-1 expression (Figure 3 Figure 5D ) and CD44 knockout mice ( Figure 5E ), although there was no significant increase in the wall thickness of the arterial AVF limb ( Figure IID and IIE in the online-only Data Supplement). AVF wall thickness was similar in WT mice treated with control microparticles and CD44 knockout mice treated with MCP-1-eluting microparticles (P=0.612). There was also significantly increased collagen and elastin immunoreactivity ( Figure 5F ), as well as increased density of α-actin ( Figure IIA in the online-only Data Supplement), in the venous AVF limb of WT and CD44 knockout mice treated with MCP-1-eluting microparticles compared with control microparticles. Similarly, there were more CD68-, transglutaminase-2-, and interleukin-10-positive cells, but not inducible nitric oxide synthase-positive cells, in the venous AVF limb of WT and CD44 knockout mice treated with MCP-1-eluting microparticles compared with control microparticles ( Figure 5F ). MCP-1 delivery also increased colocalization of transglutaminase-2 in CD68-positive cells, that is, there were increased M2 macrophages in the AVF wall ( Figure 5G ). At day 21, the AVF in WT and CD44 knockout mice showed similar numbers of PCNA (proliferating cell nuclear antigen)/α-actin and Ki67/α-actin dual-positive cells in AVF treated with control or MCP-1-eluting microparticles ( Figure III in the online-only Data Supplement), consistent with the lack of the effect of MCP-1 delivery on smooth muscle cell proliferation. In toto, these results are consistent with thicker AVF walls, increased collagen density, and increased number of M2 macrophages in AVF treated with MCP-1, that is, delivery of MCP-1 rescued the CD44 knockout phenotype.
Discussion
We show increased CD44 expression in the maturing venous limb of the AVF (Figure 1 ) and that venous wall thickening during AVF maturation depends on CD44 function (Figure 2) , suggesting a mechanistic role for CD44 in AVF maturation. CD44 also stimulates inflammation and macrophage accumulation in the adventitia of the maturing venous AVF limb (Figure 3) , with specific enhancement of M2 macrophage accumulation (Figure 4) . Delivery of MCP-1 to CD44 knockout mice rescues M2 macrophage accumulation and wall thickness ( Figure 5 ). These results suggest that CD44 regulates venous wall thickening during AVF maturation by promoting M2 macrophage accumulation in the adapting venous wall.
The primary finding of our study is that CD44 promotes accumulation of M2 macrophages, ECM deposition, and inflammation during AVF maturation, contributing to AVF venous wall thickening. Multiple studies have previously shown that inflammation regulates vascular remodeling. [15] [16] [17] CD44 is also known to have a role in inflammation and vascular biology 12, [18] [19] [20] ; however, our linkage of CD44 with AVF maturation has not been previously demonstrated. This novel association is consistent with the known roles of CD44 in regulation of cell-cell interactions, adhesion, migration, lymphocyte activation, hematopoiesis, and tumor metastasis. 8, 12, [18] [19] [20] The complex temporal expression pattern of CD44 during AVF maturation is consistent with the patterns of other regulators of AVF maturation, 5 and likely reflects the diversity of CD44's multiple cellular functions during venous remodeling. 13 In addition, the association of CD44 function with inflammation during AVF maturation occurs in the absence of significant differences in the mean blood pressure between CD44 knockout and C57BL/6J mice. 21 Interestingly, genetic deletion of CD44 shows different consequences between the venous and arterial sides of the AVF, with different degrees of outward remodeling and changes in matrix components (Figure 2) , suggesting differential roles for CD44 in veins and arteries in response to the distinct hemodynamics of the AVF. It is possible that the slightly different genetic backgrounds of C57BL/6 and CD44 knockout mice may affect the immune or inflammatory responses present during AVF maturation, despite >99.9% genetic homology after 11 backcross generations. However, C57BL/6 mice show similar arterial remodeling compared with other commonly used mouse strains. 22 In addition, C57BL/6 and CD44 knockout mice have equivalent preoperative vascular measurements (Table 2) , as well as similar postoperative AVF patency rates, consistent with previous reports that showed C57BL/6 mice are appropriate controls for CD44 knockout mice, both in vitro 13, 14 and in vivo.
14, [23] [24] [25] [26] The finding of M2 macrophages in the maturing AVF suggests a role for CD44 as a specific inflammatory mediator during AVF maturation. Although there are no previous reports describing M2 macrophages during AVF maturation, we have previously shown that M2 macrophage function may be an important mechanism regulating vein graft adaptation. 27 The presence of M2 macrophages is consistent with the early phase of AVF maturation being an adaptive remodeling response of the vein to the fistula environment, rather than a pathological response that necessarily leads to AVF failure. However, as there is considerable heterogeneity of tissue-resident macrophages, 28 it is not surprising that specific subpopulations of macrophages that are responsible for venous remodeling are not well described.
MCP-1 has been found in human AVF, 29 although the significance of MCP-1 during venous remodeling is not clearly understood. Using a jugular-to-carotid AVF model in aged mice, Juncos et al 30 previously reported that MCP-1 contributes to AVF failure, with MCP-1 knockout mice having thinner walls and increased lumen diameter. With a similar jugular-to-carotid AVF model in mice with chronic renal failure, Brahmbhatt et al 31 reported that lex-1 regulates MCP-1, with lex-1 knockout mice having reduced MCP-1 and neointimal hyperplasia. Our data show no increase in MCP-1 RNA and protein expression, as well as fewer MCP-1-positive cells, in the AVF of CD44 knockout mice (Figure 3) , suggesting that one function of CD44 is to promote macrophage accumulation in the maturing AVF limb. However, it is also noteworthy that the increase in macrophages at day 21 is preceded by increased MCP-1 expression at day 7 ( Figure 3) . Together with the observation that MCP-1 delivery stimulates wall thickening, ECM synthesis, and M2 macrophage accumulation in the AVF wall even in the absence of CD44 (Figure 5) , it is possible that inflammation that occurs during AVF maturation is stimulated by both CD44-dependent and CD44-independent pathways. The unexpected finding that delivery of MCP-1 similarly increases wall thickness, ECM synthesis, and M2 macrophage accumulation in control mice suggests that MCP-1 can drive these pathways in the presence of CD44.
In addition to the scientific importance of this alternative pathway, the significance of this finding lies in its potential clinical application to (CD44 WT) human patients needing improved AVF maturation; thus stimulation of MCP-1 activity may be a therapeutic approach translatable to human patients. As we have previously shown that our mouse aortocaval AVF model recapitulates human AVF maturation, 4 we believe that our data suggest a role for MCP-1 during AVF maturation. However, the mechanism by which MCP-1 promotes specific accumulation of M2 macrophages during venous remodeling remains to be determined.
In conclusion, CD44 promotes accumulation of M2 macrophages, ECM deposition and inflammation, enhancing AVF maturation. These data suggest that promoting CD44 activity may be a strategy to enhance AVF maturation, and also show the importance of inflammation to enable wall thickening, that is, adaptive remodeling, during AVF maturation. The use of anti-inflammatory modulators such as pharmaceutical compounds or mesenchymal stem cells may possibly be used as adjuvant therapy to decrease AVF failure rates; this work also suggests that microparticles are a potential mechanism to deliver these small molecule anti-inflammatory modulators.
